Ototoxicity from high‐dose use of platinum compounds in patients with neuroblastoma
- 5 July 2006
- Vol. 107 (2), 417-422
- https://doi.org/10.1002/cncr.22004
Abstract
BACKGROUND. The young age of neuroblastoma patients makes them especially prone to the ototoxic effects of widely used treatments that feature aggressive use of platinum compounds. We present data defining the extent of the problem in a large series of neuroblastoma patients whose induction included high‐dose cisplatin/etoposide (HD‐P/E) as used in both the Memorial Sloan‐Kettering Cancer Center N7 regimen and the Children's Oncology Group A3973 study. METHODS. N7/A3973 patients were divided into 3 groups: Group 1 had hearing tested after induction, that included 2 cycles of HD‐P/E (cumulative cisplatin = 400 mg/m2); Group 2 had hearing tested after induction, that included 3 cycles of HD‐P/E (cumulative cisplatin = 600 mg/m2); and Group 3 had hearing tested following carboplatin‐containing myeloablative therapy administered after induction, that included 2 cycles of HD‐P/E. Ototoxicity was scored by the Brock method. RESULTS. All 3 groups had similar clinical characteristics, including median age at diagnosis of about 3 years. Little or no hearing loss in the speech range (Grade 0/1) was documented in 21 (32%) of the 65 Group 1 patients, 5 (10%) of the 50 Group 2 patients, and 9 (15.5%) of the 58 Group 3 patients. Severe (Grade 3/4) deficits affected 25% of Group 1, 54% of Group 2, and 50% of Group 3 patients. Patients < 5 years at diagnosis had greater ototoxicity than older patients had, with adolescents/adults being the least affected. Findings were stable in repeated assessments over 2 or more years. CONCLUSIONS. Ototoxicity is a serious and pervasive problem in this patient population. Strategies to ameliorate ototoxicity without compromising on antitumor activity of treatments are urgently needed. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 33 references indexed in Scilit:
- Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social DevelopmentJournal of Clinical Oncology, 2005
- Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk NeuroblastomaJournal of Clinical Oncology, 2004
- Predicting cisplatin ototoxicity in children: the influence of age and the cumulative doseEuropean Journal Of Cancer, 2004
- Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adultsBone Marrow Transplantation, 2001
- Radiotherapy Enhanced Ototoxicity of Cisplatin in ChildrenActa Oto-Laryngologica, 1997
- Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescueMedical and Pediatric Oncology, 1996
- Cisplatin in children: hearing loss correlates with iris and skin pigmentationThe Journal of Laryngology & Otology, 1995
- High-dose rapid schedule chemotherapy for disseminated neuroblastomaEuropean Journal Of Cancer, 1992
- Acute Onset Deafness in a 4-Year-Old Girl After a Single Infusion of Cis-PlatinumPediatric Hematology and Oncology, 1990
- Hearing loss in children receiving cisplatin chemotherapyThe Journal of Pediatrics, 1983